Predicting Radiotherapy Response and Toxicities in Soft Tissue Sarcoma of the Extremities - Cohort B

Shown exactly as written on ClinicalTrials.gov. Your oncologist is the right person to judge whether it fits your situation.

Inclusion Criteria:

* Histopathological diagnosis of soft tissue sarcoma of the upper or lower limb or limb girdle;
* Patients receiving pre-operative (neo-adjuvant), post-operative (adjuvant) or palliative radiotherapy;
* Patients receiving radiotherapy planned as per local protocols (neoadjuvant chemotherapy will be allowed). Neoadjuvant chemotherapy patients may be approached as they commence chemotherapy;
* WHO performance status 0-2;
* Aged ≥16 years;
* Patients fit enough to undergo radiotherapy treatment and willing to attend follow up visits, during two years;
* Female patients of child-bearing potential and male patients with partners of child-bearing potential must agree to use adequate contraception methods, which must be continued for 3 months after completion of treatment;
* Capable of giving written informed consent.

Exclusion Criteria:

* Previous radiotherapy to the same site;
* Pregnancy;
* Patients with concurrent or previous malignancy that could compromise assessment of primary and secondary endpoints of the trial.